Sibylla Biotech raises €23m Series A
Verona-based Sibylla Biotech has closed a €23m Series A financing round to advance its Pharmacological Protein Inactivation by Folding Intermediate Targeting (PPI-FIT) platform.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2060 entries already.
Entries by Thomas Gabrielczyk
AI expert XUND GmbH bags €6m seed financing
Austrian XUND GmbH wants to use the assets of a €6m seed financing to grow in Germany, Switzerland and Austria.
The BIOTECH Insight Newsletter presents news from biotechnology and german stock market
In the present newsletter special issues will be reinforced and personality of branches interviewed. Financing in sustainable production (#BRAIN_AG), synBio and AI (AIgnostics) are highlights in the Biotech Newsletter of Deutsche Börse AG.
ADC makeer Pheon Therapeutics raises $68m
Antibody-Drug Conjugate (ADC) specialist Pheon Therapeutics Ltd. has closed a $68m Series A financing co-led by Brandon Capital, Forbion and Atlas Venture.
Non-viral is better
Immunogenicity and limited gene transfer capacity can negatively affect the outcome of cell and gene therapies. European Biotechnology magazine spoke to Dr Dimitrios Laurin Wagner, Berlin Center for Advanced Therapies (BeCAT) and Gene Editing for Cell Therapy group leader at Charité, on new approaches that promise to overcome some limitations of current virus-based gene therapies.
2nd European Symposium on Ultrafast Laser driven Biophotonics was a great success!
nearly 200 participants
from 23 countries
30 posters
28 talks
Kupando raises €13m to push TLR4/7 agonist
Kupando has raised €13m in Series A financing co-led by Remiges Ventures and LifeCare Partners to initiate clinical development of KUP101.
DAMAN P/S enters personal RA medicine project
Danish AI health app developer DAMAN P/S has entered the €12m EU-funded Squeeze project, that aims to find stratification biomarkers for DMARDs in rheumatoid arthritis (RA).
Transformative innovation in drug development
The technological and pharmacological advances lead to an increase in the number of molecules for R&D that are challenging and difficult to manufacture. To improve clinical success, pharma and biotech companies are seeking innovative ways to accelerate progress and reduce scientific, economic, and delivery risks.
AI specialist Quinten Health bags €14m financing
Quinten Group’s French healthcare arm Quinten Health has closed a financing round to advance disease modeling platforms and virtual twins in real-world.